Advancing Early‐Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring Authors: Chantal Mathieu, Valentino Cherubini, Thomas Kapellen, Noemí González Pérez de Villar, Guendalina Graffigna, Alix Besancon, Alfred Penfornis, Justin Gregory, Monica Bertolini, Maria Asunción Martinez‐Brocca, Korey Hood, Tabitha Randell, Ralph Ziegler, Parth Narendran, Carla Demeterco‐Berggren Published: 2026 ABSTRACT ABSTRACTBackgroundAlthough international guidelines provide recommendations for screening and monitoring of early‐stage type 1 diabetes (T1D), navigating the care pathway can still be difficult for individuals, caregivers, and healthcare professionals (HCPs). These challenges are exacerbated by variations in healthcare systems, gaps in communication, and limited psychosocial support.AimsThis manuscript aims to bridge the gap between theory and clinical practice and present practical, stage‐specific recommendations for early‐stage T1D care in pediatric and adult populations.Materials and MethodsThis article was informed by a structured literature review, qualitative interviews with HCPs in the UK, Germany, France, Italy, and Spain, and multidisciplinary expert input from the CARE‐T1D working group. The group comprised six pediatric and six adult endocrinologists, and two psychologists from the EU, UK, and US.Results, Discussion and ConclusionHere we present proposed care pathways for pediatric and adult early‐stage T1D, integrating recommendations for clear communication, care coordination, and psychosocial support throughout. This manuscript is intended to support the standardization of early‐stage T1D detection and monitoring, thereby contributing to improved outcomes, including reducing the incidence of diabetic ketoacidosis (DKA) and hospitalization at stage 3 T1D diagnosis.Keywords: diabetes complications, disease prevention, perceptions, primary care, type 1 diabetes Introduction T1D is an autoimmune condition characterized by the progressive loss of pancreatic beta‐cell function [1]. Accordingly, the presence of islet autoantibodies is indicative of T1D and sufficient for detection of early‐stage (presymptomatic) disease, which can then be formally diagnosed and staged through metabolic testing (Figure 1) [2, 9]. In the case of adults with early‐stage T1D, where symptoms of dysglycemia may masquerade as type 2 prediabetes, islet autoantibody testing has the potential to prevent misclassification [2, 9]. Stages of T1D [2, 3, 4, 5, 6, 7, 8]. Figure modified from Insel et al. [4]. C‐peptide, connecting peptide; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IAb, islet autoantibody; OGTT, oral glucose tolerance test; T1D, type 1 diabetes. †Normoglycemia: FPG < 100 mg/dL (< 5.6 mmol/L); 120‐min OGTT < 140 mg/dL (< 7.8 mmol/L); HbA1c < 39 mmol/mol (< 5.7%); Dysglycemia: FPG 100–125 mg/dL (5.6–6.9 mmol/L); 120‐min OGTT 140–199 mg/dL (7.8–11.0 mmol/L); HbA1c 39–47 mmol/mol (5.7%–6.4%) or ≥ 10% rise from baseline; Hyperglycemia: FPG ≥ 126 mg/dL (≥ 7.0 mmol/L); 120‐min OGTT ≥ 200 mg/dL (≥ 11.1 mmol/L); random glucose ≥ 200 mg/dL (≥ 11.1 mmol/L) with symptoms; HbA1c ≥ 48 mmol/mol (≥ 6.5%) [2]. ‡ American Diabetes Association 2025 guidelines note that IAbs are usually multiple, and that in stage 3, IAbs may become absent [8]. §People can fluctuate between stages [7]. Proof of principle has been established in large screening initiatives for early‐stage T1D screening, both for higher‐likelihood individuals and the general population. The Fr1da study in Germany and the Early Surveillance for Autoimmune Diabates (ELSA) study in the UK both screened children according to age, with the Fr1da study integrating screening into routine care [10, 11]. The TrialNet Pathway to Prevention of T1D study, conducted across North America, Europe, and Australia, offers screening to higher‐likelihood individuals with a family history of T1D and/or prior autoantibody positivity [12, 13]. The Environmental Determinants of Diabetes in the Young (TEDDY) study in North America and Europe includes both children from the general population and those with a family history of T1D, while the Type 1 Diabetes Risk in Adults (T1DRA) study assesses risk in adults sampled from the UK general population [14, 15]. Taken together, these programs support the feasibility and clinical rationale for structured screening and follow‐up. However, there is a need to distinguish population‐based approaches from targeted testing when translating screening programs into routine care pathways. To facilitate clinical implementation, several organizations have developed consensus guidance for early T1D detection (see Supporting Information for further details). However, current challenges in translating guidance to clinical practice within healthcare systems for HCPs can lead to a lack of cohesion between steps of care and referral pathways, and barriers in communication [2, 9]. In the authors' experience, this can make navigating the care pathway overwhelming, leading to frustration and anxiety from a patient and caregiver perspective. Here we propose an adaptable framework for both adult and pediatric care of T1D, to provide practical guidance to support primary care providers (PCPs) and other HCPs in implementing who to screen, when to screen, and how to manage individuals identified with early‐stage T1D, including appropriate monitoring and referral. Application of these pathways is intended to improve the experience of patients and caregivers and facilitate timely diagnosis and appropriate follow‐up. While the overall steps in care for both the adult and pediatric T1D care pathway are similar, nuances exist, which are highlighted throughout this article. Furthermore, it is important to note that the steps described here will be carried out by different stakeholders within care settings (primary, secondary, tertiary), depending on the organization of the healthcare system and local guidelines. Proposed clinical guidance for HCPs is presented within the tables of this manuscript. Additionally, education and communication guidance is provided throughout. This article is a global publication intended as a guiding document. HCPs should use appropriate judgement to adapt their approaches to the nuances of their countries and healthcare systems. Methods Three key sources informed this article: Literature review: [16, 17] A structured PubMed search was conducted to identify evidence on early‐stage T1D, focusing primarily on 2023–2025 publications and, where needed, earlier landmark guidelines. Search terms included early‐stage T1D (e.g., presymptomatic/preclinical T1D, stage 1, stage 2, and autoimmune diabetes) and care delivery (e.g., screening programs, autoantibody testing, dysglycemia monitoring, patient pathways, and psychosocial impact). Additional sources (conference proceedings, guidelines, white papers, and program evaluations) were identified via citation tracking and expert recommendation. Records were screened by title/abstract for relevance to T1D screening, monitoring, early detection, or diagnosis. Full texts were assessed against predefined inclusion criteria: (a) relevance to presymptomatic, preclinical, stage 1 or stage 2 T1D; (b) screening/monitoring/early detection, pathways, or autoantibody testing; and (c) provision of guidance, consensus, best practices, or clinical recommendations. Key data were extracted in a structured format and synthesized thematically and by pathway stage. Literature review: [16, 17] A structured PubMed search was conducted to identify evidence on early‐stage T1D, focusing primarily on 2023–2025 publications and, where needed, earlier landmark guidelines. Search terms included early‐stage T1D (e.g., presymptomatic/preclinical T1D, stage 1, stage 2, and autoimmune diabetes) and care delivery (e.g., screening programs, autoantibody testing, dysglycemia monitoring, patient pathways, and psychosocial impact). Additional sources (conference proceedings, guidelines, white papers, and program evaluations) were identified via citation tracking and expert recommendation. Records were screened by title/abstract for relevance to T1D screening, monitoring, early detection, or diagnosis. Full texts were assessed against predefined inclusion criteria: (a) relevance to presymptomatic, preclinical, stage 1 or stage 2 T1D; (b) screening/monitoring/early detection, pathways, or autoantibody testing; and (c) provision of guidance, consensus, best practices, or clinical recommendations. Key data were extracted in a structured format and synthesized thematically and by pathway stage. Records were screened by title/abstract for relevance to T1D screening, monitoring, early detection, or diagnosis. Full texts were assessed against predefined inclusion criteria: (a) relevance to presymptomatic, preclinical, stage 1 or stage 2 T1D; (b) screening/monitoring/early detection, pathways, or autoantibody testing; and (c) provision of guidance, consensus, best practices, or clinical recommendations. Key data were extracted in a structured format and synthesized thematically and by pathway stage. Records were screened by title/abstract for relevance to T1D screening, monitoring, early detection, or diagnosis. Full texts were assessed against predefined inclusion criteria: (a) relevance to presymptomatic, preclinical, stage 1 or stage 2 T1D; (b) screening/monitoring/early detection, pathways, or autoantibody testing; and (c) provision of guidance, consensus, best practices, or clinical recommendations. Key data were extracted in a structured format and synthesized thematically and by pathway stage. Primary qualitative insights: Semi‐structured interviews were conducted (non‐compensated) with HCPs in the UK, Germany, France, Italy, and Spain. Participants were recruited through clinical networks and participating hospitals. Interviews explored practical, clinical, and psychosocial challenges related to early detection and monitoring in early‐stage T1D. Primary qualitative insights: Semi‐structured interviews were conducted (non‐compensated) with HCPs in the UK, Germany, France, Italy, and Spain. Participants were recruited through clinical networks and participating hospitals. Interviews explored practical, clinical, and psychosocial challenges related to early detection and monitoring in early‐stage T1D. CARE‐T1D working group: The multidisciplinary CARE‐T1D working group, comprising six pediatric endocrinologists, six adult endocrinologists, and two psychologists from the EU, UK, and US, convened for three meetings to develop proposed care pathways and recommendations for adults and children with early‐stage T1D. The group reviewed existing guidelines, prioritized interventions, and identified, mapped, and focused on key barriers—particularly to screening—drawing on a targeted literature review and primary qualitative insights to inform the final recommendations. All members of the CARE‐T1D working group are co‐authors of this manuscript. CARE‐T1D working group: The multidisciplinary CARE‐T1D working group, comprising six pediatric endocrinologists, six adult endocrinologists, and two psychologists from the EU, UK, and US, convened for three meetings to develop proposed care pathways and recommendations for adults and children with early‐stage T1D. The group reviewed existing guidelines, prioritized interventions, and identified, mapped, and focused on key barriers—particularly to screening—drawing on a targeted literature review and primary qualitative insights to inform the final recommendations. All members of the CARE‐T1D working group are co‐authors of this manuscript. Key Considerations for Care in Early‐Stage T1D Proposed care pathways for adults and children with early‐stage T1D were developed from identification, through obtaining consent, education and screening, and monitoring. The care pathways represent a seamless process for early‐stage T1D care, identifying roles and responsibilities for different HCPs and practical steps for implementation. A simplified version of the combined pathway with HCP roles is shown in Figure 2. Simplified proposed care pathway with mapped healthcare professional roles from disease awareness & initial identification to screening & staging and monitoring. Schematic representing the proposed care pathway. IAbs, islet autoantibodies; OGTT, oral glucose tolerance test; T1D, type 1 diabetes. Implementation of the pathway may vary widely between healthcare systems due to differences in resource availability, workforce capacity, and referral structures [9, 18]. Detection of early‐stage T1D may be delivered in diverse settings including primary care, specialist clinics, private practices, or large healthcare organizations [9]. These differences influence practical aspects such as methods for blood collection, follow‐up procedures, and communication tools [9]. With these limitations in mind, the authors developed pathways containing three key sections: Disease Awareness and Initial Identification, Screening and Staging, and Monitoring (Figures 2, 3, 4, 5 and S1). Overview of pathway—disease awareness and initial identification. FDR, first‐degree relative; PCP, primary care provider; SDR, second‐degree relative; T1D, type 1 diabetes. Overview of pathway—screening and staging. HCP, healthcare professional; IAb, islet autoantibody; OGTT, oral glucose tolerance test; PCP, primary care provider; STC, secondary/tertiary care; T1D, type 1 diabetes. †Individual only invited for early detection testing if it hasn't already been conducted in adulthood. Overview of pathway—monitoring. HCP, healthcare professional; IAb, islet autoantibody; OGTT, oral glucose tolerance test; PCP, primary care provider; STC, secondary/tertiary care; T1D, type 1 diabetes. While the proposed framework positions PCPs as key partners in early‐stage T1D detection and monitoring, it is important to note that in many settings, PCPs may not yet have the training, resources, or established referral pathways to take on this role effectively [19]. Addressing these gaps, such as through targeted education, development of clear clinical protocols, and integration with specialist support, is essential for real‐world implementation, and to prepare healthcare systems and PCPs to engage in early detection initiatives. Disease Awareness and Initial Identification Ongoing educational efforts, public campaigns, and social media are raising awareness of screening for T1D, which may lead to individuals requesting testing from their healthcare provider. While direct empirical data demonstrating this in T1D are currently limited, outreach approaches used in large screening programs suggest that optimizing recruitment strategies may increase engagement and participation. Recent findings from the ELSA study demonstrate the feasibility and early outcomes of implementing multiple recruitment routes for general population screening in the UK, offering opportunities to refine future population screening programs in the UK and internationally [20]. Between November 2022 and 2024, the ELSA study successfully recruited 24 875 children, with 17 283 dried blood spot cards analyzed and results returned to families [20]. Recruitment largely occurred via social media, schools, and general practitioners, with testing predominantly taking place at home (62%) or in schools (22%) [20]. Notably, the ELSA study's use of other recruitment and testing settings, such as schools, general practices, and hospitals, led to increased participation from ethnic minority groups, populations in more deprived areas, and those without a family history of T1D [20]. Other screening programs like TrialNet, using social media, a blog, and screening events, have screened over 250 000 individuals while the Fr1da study (by leveraging routine primary‐care well‐child visits) has successfully implemented population‐wide screening at scale, testing > 90 000 children across 4 years [10, 21, 22]. Building on the success of these outreach efforts, HCPs should consider offering testing to people with a higher chance of developing T1D—for example, people with first‐degree relatives (FDRs) living with T1D have a ~10–15‐fold increased likelihood of developing T1D compared with the general population [23]. Focusing on these relatives initially may be particularly effective, as they tend to be more engaged and invested in the process [20]. Other groups at higher risk include second‐degree relatives of people with T1D, or those living with autoimmune diseases such as celiac disease, hyperthyroidism, or Hashimoto's disease, or those with increased genetic risk [8, 18, 24, 25]. Screening can be proposed in pediatric settings during routine childhood appointments, or when dysglycemia is identified in adults and T1D is suspected [8, 10]. In the Fr1da study, < 5% of screened children with stage 3 T1D presented with DKA [10]. In contrast, population‐level data from Germany indicate a DKA rate at diagnosis of > 20% in unscreened children [10]. Despite data suggesting that screening can reduce the risk of presentation with DKA, some individuals may still be hesitant to be screened [26]. This reluctance can stem from anxiety about results, low perceived value of screening, and concerns about the impact of a diagnosis on daily life, including potential financial, employment, and insurance considerations [2, 19, 26]. For HCPs, limited familiarity with early‐stage T1D, uncertainty about screening, discomfort with discussing results, and competing clinical priorities can contribute to reluctance in recommending or facilitating testing [19, 26]. Further details on the Disease Awareness and Initial Identification section of the care pathway, as well as key considerations for HCPs, are shown in Figure 3 and Table 1, respectively. TABLE 1Key considerations for HCPs – disease awareness and initial identification.Disease awareness and initial identification [8] (Primary, secondary, tertiary setting and any other settings [e.g., schools]) Explain that T1D can be detected before symptoms developProvide explanation of the benefits and limitations of screening and highlight that population‐based screening approaches are preferred over physician‐initiated screening, where available (i.e., explain that early detection can reduce the risk of DKA, with the reduction dependent on participation in monitoring)If part of a national screening program, follow guidance on how to communicate results to parents/caregivers of childrenCommunicate clearly that individual is eligible for early detection screeningProvide fear‐free, neutral educational materials for families, ensuring that materials include psychosocial supportInform of the likelihood for confirmatory testing DKA, diabetic ketoacidosis; HCP, healthcare professional; T1D, type 1 diabetes. Key considerations for HCPs – disease awareness and initial identification. Explain that T1D can be detected before symptoms developProvide explanation of the benefits and limitations of screening and highlight that population‐based screening approaches are preferred over physician‐initiated screening, where available (i.e., explain that early detection can reduce the risk of DKA, with the reduction dependent on participation in monitoring)If part of a national screening program, follow guidance on how to communicate results to parents/caregivers of childrenCommunicate clearly that individual is eligible for early detection screeningProvide fear‐free, neutral educational materials for families, ensuring that materials include psychosocial supportInform of the likelihood for confirmatory testing Explain that T1D can be detected before symptoms develop Explain that T1D can be detected before symptoms develop Provide explanation of the benefits and limitations of screening and highlight that population‐based screening approaches are preferred over physician‐initiated screening, where available (i.e., explain that early detection can reduce the risk of DKA, with the reduction dependent on participation in monitoring) Provide explanation of the benefits and limitations of screening and highlight that population‐based screening approaches are preferred over physician‐initiated screening, where available (i.e., explain that early detection can reduce the risk of DKA, with the reduction dependent on participation in monitoring) If part of a national screening program, follow guidance on how to communicate results to parents/caregivers of children If part of a national screening program, follow guidance on how to communicate results to parents/caregivers of children Communicate clearly that individual is eligible for early detection screening Communicate clearly that individual is eligible for early detection screening Provide fear‐free, neutral educational materials for families, ensuring that materials include psychosocial support Provide fear‐free, neutral educational materials for families, ensuring that materials include psychosocial support Inform of the likelihood for confirmatory testing Inform of the likelihood for confirmatory testing DKA, diabetic ketoacidosis; HCP, healthcare professional; T1D, type 1 diabetes. Screening and Staging Initial Screening and Confirmatory Testing There are four primary islet autoantibodies detected in clinical care that can indicate early‐stage T1D: insulin autoantibody (IAA), insulinoma‐associated antigen 2 autoantibody (IA‐2A), glutamic acid decarboxylase autoantibody (GADA), and zinc‐transporter 8 autoantibody (ZnT8A) [2, 27]. However, diagnosing and managing early‐stage T1D in adults can present particular challenges beyond those encountered in pediatric populations. Notably, due to the higher prevalence of type 2 diabetes (T2D) in adults compared with T1D, there is potential for misclassification [28]. Furthermore, cases of T1D presenting later in life are sometimes labelled as latent autoimmune diabetes in adults (LADA), though there remains debate about whether there are distinct epidemiological, clinical, or pathophysiological differences between adult‐onset T1D and LADA [29]. This lack of clarity may also lead to potential misclassification and suboptimal treatment [29]. Recommendations on testing for islet autoantibodies, including assay selection, are provided by recent clinical guidelines and consensus statements (see Supporting Information for further details) [2, 8]. HCPs ordering tests should contact their local laboratories to identify available testing methods, with consideration that more sensitive assays may be useful for screening and more specific assays for confirmation [2, 30, 31]. In some settings, referral to secondary care may occur, requiring HCPs to clearly communicate the expected process with the individual being tested [2]. Furthermore, additional research is needed to identify clinical features, beyond islet autoantibody testing, that could help distinguish autoimmune diabetes from T2D in adults and support appropriate diagnosis, referral, and monitoring [28]. The many steps involved in testing (Figure 4), coupled with gaps between primary and secondary care, and unclear referral pathways can result in delays or loss to follow‐ups [9]. Ideally, an HCP should be designated as a dedicated point of contact to provide information and support for individuals and caregivers undergoing testing. Similarly, primary care “diabetes champions” can liaise with secondary care providers to streamline referrals, while use of shared electronic health record alerts and standardized referral protocols can ensure visibility for all relevant HCPs [9, 32]. Following confirmation of the presence of ≥ 2 islet autoantibodies, metabolic testing is required to determine T1D stage (Figure 4) [7]. Staging enables assessment of disease progression, informs monitoring frequency, and helps identify when more intensive follow‐up may be needed, particularly for individuals in stage 2 who are at greater short‐term risk of progression [7, 33]. Staging The Oral Glucose Tolerance Test (OGTT) remains the gold standard for staging individuals with ≥ 2 islet autoantibodies and assessing disease progression [7]. However, in practice it is often difficult to implement, particularly in children [2]. Where OGTT is impractical or unavailable, a transition to less burdensome metabolic measures can support ongoing monitoring, especially in under‐resourced settings [7]. The International Society for pediatric and Adolescent Diabetes (ISPAD) and Breakthrough T1D consensus guidance indicate that alternative approaches such as HbA1c (haemoglobin A1c) and capillary or venous glucose measures (fasting, random, or 2‐h postprandial) can provide clinically useful information, alongside self‐monitored blood glucose (SMBG) and periodic continuous glucose monitoring (CGM) [2, 7]. Fasting serum blood glucose may be used within this approach where laboratory testing is available, offering a lower‐burden alternative to OGTT [7]. In settings relying on HbA1c‐based monitoring, clinicians should recognize that HbA1c is often normal early in disease and should be interpreted in combination with glucose measures and clinical context [2]. Where practicable, CGM may be used in conjunction with, or in place of, HbA1c to provide real‐time glucose patterns and support earlier detection of dysglycemia [2, 7]. CGM metrics have been proposed in consensus guidance for staging stage 2 or 3 T1D; however, are not currently included in the American Diabetes Association or ISPAD staging criteria (as their use did not achieve consensus within the expert panel), nor are they considered superior to OGTT in research trial context [2, 7]. Notably, participation in prevention programs generally requires OGTT‐based staging, but for routine clinical follow‐up, these stepwise alternatives may reduce procedural and time burdens [7]. In addition to test selection, providing clear information and structured education in preparation for metabolic testing may help reduce practical barriers and support engagement. For example, in the Fr1da study, families were invited to participate in metabolic staging alongside an education program delivered at a pediatric diabetes clinic [10]. 220 of 261 eligible children (~84%) underwent metabolic staging, with 41 families declining, indicating a high level of engagement with the clinic‐based staging and education pathway [10]. Children with stage 1 T1D have a substantial risk of progression, with around 44% developing stage 3 T1D within 5 years and up to 80%–90% within 15 years [7]. By contrast, approximately 75% of those in stage 2 progress within 5 years and nearly all will do so over their lifetime [7]. Importantly, this progression can occur in the absence of symptoms and often presents with DKA, which affects 25% of children and 9%–11% of adults at diagnosis in the UK and is associated with serious complications [2, 7, 34]. HCPs should communicate these risks to families, emphasizing the importance of ongoing monitoring to prepare for potential disease progression and reduce the likelihood of DKA. Effective coordination across primary, secondary, and tertiary care is therefore critical to ensure timely monitoring, preparedness for progression, and a cohesive experience for individuals and caregivers (see Figure 4 and Table 2 for an overview of the Screening and Staging section of the pathway and the key considerations for HCPs, respectively). TABLE 2Key considerations for HCPs – screening and staging.Testing and confirmatory testing Individual and/or caregiver informed of islet autoantibody testing for T1D (Primary, secondary, or tertiary setting) Provide a brief explanation of the steps in the testing process (e.g., first test, confirmatory test, and then diagnosis)Use neutral, fear‐free language and if available, provide written materials outlining screening objectives, procedures, follow‐up, and rescreeningInform individual/caregiver of expected result turnaround time and communication planSet clear expectations about additional blood collections Consent obtained from individual/caregiver for islet autoantibody testing (Primary, secondary, or tertiary setting) Obtain consent following local protocolsIf consent is refused, offer educational materials and note that screening can be reconsidered later Order blood sample for islet autoantibody testing (Primary, secondary, or tertiary setting) Provide clear instructions for sample collection and confirm funding/coverageFollow kit protocols for collection, ensuring sample integrity (drying, labeling, packaging). For FDRs screened in hospital settings, venous blood collection may be used in place of kit‐based samplingSend samples to accredited labs Communicate islet autoantibody test results (if islet autoantibodies are not present) (Primary, secondary, or tertiary setting) Deliver results using a letter or textProvide a brief explanation that this result does not preclude future risk of T1D and that rescreening may be recommended depending on a range of factors (e.g., age)Review the characteristic signs and symptoms of T1D with families, emphasizing the importance of early detection and rapid assessment should these features ariseAdvise on recommended rescreening intervals and educate on T1D symptoms that require prompt medical attention (Figure 4) Communicate islet autoantibody test results (if islet autoantibodies are present) and invite for confirmatory test (Secondary or tertiary setting) Deliver results in person or by phone, with experienced HCPs explaining the findings and need for confirmatory testing using clear, neutral language and toneProvide a brief explanation of the immediate next steps in the processRefer to a specialist center for further evaluation and/or consideration of a clinical trialSet expectations and develop approach for metabolic monitoring and consistent follow‐ups Confirmatory testing Conduct confirmatory venous blood sample test (Secondary or tertiary setting) Collect venous blood sample as recommended for confirmation, following local protocols to select collection location according to age and individual characteristics, and ensuring proper labelling and chain of custody for samplesIf capability is limited, ensure appropriate referral for testing Communicate confirmatory islet autoantibody test results (Primary, secondary, or tertiary setting) Communicate results as per previous stepsIf appropriate, refer to expert center for staging and diagnosis Prepare for metabolic testing (Primary, secondary, or tertiary setting) Schedule follow‐up appointment or referralProvide individuals and caregivers with information on next steps Staging Arrange and/or conduct OGTT or other staging test (Secondary or tertiary setting) Provide a brief explanation on the next immediate steps (e.g., information about OGTT) and ensure individuals and caregivers understand the current stage, what it means for ongoing monitoring, and what signs or symptoms could indicate progression to the next stageIf able, perform the test according to standard protocols, providing clear preparation instructions (e.g., fasting requirements, duration of test) beforehandIf not able, refer to a specialist center Review OGTT/staging test results upon completion (Secondary setting) Assess for and act on any immediate risk (e.g., impending DKA)Interpret test results to determine the individual's T1D stage Communicate T1D diagnosis (stage 1, 2 or 3) and provide education Deliver the diagnosis clearly to the individual/caregiver and the individual's primary care provider when conducted in a specialist settingProvide an explanation on the specific stage of T1D and what it means for their healthIf available, provide written education materials (with neutral, fear‐free language) on early‐stage T1D, how it's monitored, and next stepsOffer psychosocial support resources and a referral from the diabetes care team where necessaryUse empathetic, clear language when discussing with individual/caregiverProvide education on the timeframe for receiving results Abbreviations: DKA, diabetic ketoacidosis; FDR, first‐degree relative; HCP, healthcare professional; OGTT, oral glucose tolerance test; T1D, type 1 diabetes. Key considerations for HCPs – screening and staging. Individual and/or caregiver informed of islet autoantibody testing for T1D (Primary, secondary, or tertiary setting) Provide a brief explanation of the steps in the testing process (e.g., first test, confirmatory test, and then diagnosis) Provide a brief explanation of the steps in the testing process (e.g., first test, confirmatory test, and then diagnosis) Use neutral, fear‐free language and if available, provide written materials outlining screening objectives, procedures, follow‐up, and rescreening Use neutral, fear‐free language and if available, provide written materials outlining screening objectives, procedures, follow‐up, and rescreening Inform individual/caregiver of expected result turnaround time and communication plan Inform individual/caregiver of expected result turnaround time and communication plan Set clear expectations about additional blood collections Set clear expectations about additional blood collections Consent obtained from individual/caregiver for islet autoantibody testing (Primary, secondary, or tertiary setting) Obtain consent following local protocols Obtain consent following local protocols If consent is refused, offer educational materials and note that screening can be reconsidered later If consent is refused, offer educational materials and note that screening can be reconsidered later Order blood sample for islet autoantibody testing (Primary, secondary, or tertiary setting) Provide clear instructions for sample collection and confirm funding/coverage Provide clear instructions for sample collection and confirm funding/coverage Follow kit protocols for collection, ensuring sample integrity (drying, labeling, packaging). For FDRs screened in hospital settings, venous blood collection may be used in place of kit‐based sampling Follow kit protocols for collection, ensuring sample integrity (drying, labeling, packaging). For FDRs screened in hospital settings, venous blood collection may be used in place of kit‐based sampling Send samples to accredited labs Send samples to accredited labs Communicate islet autoantibody test results (if islet autoantibodies are not present) (Primary, secondary, or tertiary setting) Deliver results using a letter or text Deliver results using a letter or text Provide a brief explanation that this result does not preclude future risk of T1D and that rescreening may be recommended depending on a range of factors (e.g., age) Provide a brief explanation that this result does not preclude future risk of T1D and that rescreening may be recommended depending on a range of factors (e.g., age) Review the characteristic signs and symptoms of T1D with families, emphasizing the importance of early detection and rapid assessment should these features arise Review the characteristic signs and symptoms of T1D with families, emphasizing the importance of early detection and rapid assessment should these features arise Advise on recommended rescreening intervals and educate on T1D symptoms that require prompt medical attention (Figure 4) Advise on recommended rescreening intervals and educate on T1D symptoms that require prompt medical attention (Figure 4) Communicate islet autoantibody test results (if islet autoantibodies are present) and invite for confirmatory test (Secondary or tertiary setting) Deliver results in person or by phone, with experienced HCPs explaining the findings and need for confirmatory testing using clear, neutral language and tone Deliver results in person or by phone, with experienced HCPs explaining the findings and need for confirmatory testing using clear, neutral language and tone Provide a brief explanation of the immediate next steps in the process Provide a brief explanation of the immediate next steps in the process Refer to a specialist center for further evaluation and/or consideration of a clinical trial Refer to a specialist center for further evaluation and/or consideration of a clinical trial Set expectations and develop approach for metabolic monitoring and consistent follow‐ups Set expectations and develop approach for metabolic monitoring and consistent follow‐ups Conduct confirmatory venous blood sample test (Secondary or tertiary setting) Collect venous blood sample as recommended for confirmation, following local protocols to select collection location according to age and individual characteristics, and ensuring proper labelling and chain of custody for samples Collect venous blood sample as recommended for confirmation, following local protocols to select collection location according to age and individual characteristics, and ensuring proper labelling and chain of custody for samples If capability is limited, ensure appropriate referral for testing If capability is limited, ensure appropriate referral for testing Communicate confirmatory islet autoantibody test results (Primary, secondary, or tertiary setting) Communicate results as per previous steps Communicate results as per previous steps If appropriate, refer to expert center for staging and diagnosis If appropriate, refer to expert center for staging and diagnosis Prepare for metabolic testing (Primary, secondary, or tertiary setting) Schedule follow‐up appointment or referral Schedule follow‐up appointment or referral Provide individuals and caregivers with information on next steps Provide individuals and caregivers with information on next steps Arrange and/or conduct OGTT or other staging test (Secondary or tertiary setting) Provide a brief explanation on the next immediate steps (e.g., information about OGTT) and ensure individuals and caregivers understand the current stage, what it means for ongoing monitoring, and what signs or symptoms could indicate progression to the next stage Provide a brief explanation on the next immediate steps (e.g., information about OGTT) and ensure individuals and caregivers understand the current stage, what it means for ongoing monitoring, and what signs or symptoms could indicate progression to the next stage If able, perform the test according to standard protocols, providing clear preparation instructions (e.g., fasting requirements, duration of test) beforehand If able, perform the test according to standard protocols, providing clear preparation instructions (e.g., fasting requirements, duration of test) beforehand If not able, refer to a specialist center If not able, refer to a specialist center Review OGTT/staging test results upon completion (Secondary setting) Assess for and act on any immediate risk (e.g., impending DKA) Assess for and act on any immediate risk (e.g., impending DKA) Interpret test results to determine the individual's T1D stage Interpret test results to determine the individual's T1D stage Deliver the diagnosis clearly to the individual/caregiver and the individual's primary care provider when conducted in a specialist setting Deliver the diagnosis clearly to the individual/caregiver and the individual's primary care provider when conducted in a specialist setting Provide an explanation on the specific stage of T1D and what it means for their health Provide an explanation on the specific stage of T1D and what it means for their health If available, provide written education materials (with neutral, fear‐free language) on early‐stage T1D, how it's monitored, and next steps If available, provide written education materials (with neutral, fear‐free language) on early‐stage T1D, how it's monitored, and next steps Offer psychosocial support resources and a referral from the diabetes care team where necessary Offer psychosocial support resources and a referral from the diabetes care team where necessary Use empathetic, clear language when discussing with individual/caregiver Use empathetic, clear language when discussing with individual/caregiver Provide education on the timeframe for receiving results Provide education on the timeframe for receiving results Abbreviations: DKA, diabetic ketoacidosis; FDR, first‐degree relative; HCP, healthcare professional; OGTT, oral glucose tolerance test; T1D, type 1 diabetes. It's important to note that effective translation of screening and staging from research programs into routine clinical care requires addressing sustainability and access challenges. Large initiatives, such as the Fr1da study and the TEDDY study, provide grant‐supported infrastructure for screening and longitudinal follow‐ups, with participating sites reimbursed for staging and follow‐up visits in the Fr1da study [10, 14]. However, in real‐world health systems, expenses may fall to families and providers. Reported financial burdens include lost income due to time off for monitoring and follow‐up, the ongoing need to attend repeated appointments, out‐of‐pocket costs, and challenges with health insurance, credit ratings, and job prospects [35]. From a health system perspective, costs include laboratory screening and confirmation, healthcare provider time, and prolonged monitoring for dysglycemia and progression [35]. To illustrate the scale of resources involved, the Fr1da study estimated total program costs of €28.17 for each child screened and €9117 for each child diagnosed with presymptomatic T1D, compared with estimates of €21.73 and €7035 for each child screened and diagnosed, respectively, under standard care [35]. Given the high costs associated with screening, staging, and follow‐up, pathways must ensure sustainable funding and equitable access for consistent implementation beyond research settings. Monitoring Monitoring of individuals diagnosed with early‐stage T1D is essential to identify progression from stage 1 or 2 to stage 3, prevent DKA at stage 3, and ensure timely preparedness for clinical onset [2]. Beyond detecting progression and preventing DKA, monitoring visits can also assess eligibility for prevention trials and, where available, early interventions to delay onset [7]. These visits provide an opportunity for counselling on a healthy diet and physical activity, which may reduce obesity‐related insulin resistance [36]. To counteract the “accelerator hypothesis”, which proposes that excess weight can increase stress on islets in genetically at‐risk individuals and accelerate autoimmune diabetes—lifestyle counselling can be incorporated during monitoring [36]. This approach can empower patients and families to make healthier choices, potentially slowing disease progression and reducing long‐term metabolic risk [36]. Recommended monitoring frequency and tests to conduct, based on disease stage and risk profile, are summarized in Table 3. However, the exact frequency and methods of monitoring should be determined according to the latest guidelines and tailored to the individual's disease progression. See Figure 5 and Table 4 for practical steps and key considerations for HCPs, respectively, for monitoring in the early‐stage T1D care pathway. TABLE 3Type of tests & frequency of monitoring. a Abbreviations: CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c; NA, non‐applicable; OGTT, oral glucose tolerance test; SMBG, self‐monitored blood glucose; T1D, type 1 diabetes. a Recommendations presented in Table 3 adapted from “Consensus guidance for monitoring individuals with islet autoantibody‐positive pre‐stage 3 type 1 diabetes” [2] and “The T1D Early Detection Toolkit: A Practical Guide to Establishing Islet Autoantibody Screening Programs” [37]. b Adjust frequency based on individual risk assessment, based on age number and type of islet autoantibodies, and glycemic status [2, 37]. c In children with stage 1 T1D, this can be a sign of disease progression even if the 10% HbA1c increase is within the normal range (e.g., from 31 mmol/mol [5.0%] to 37 mmol/mol [5.5%]) [2]. Type of tests & frequency of monitoring. a Abbreviations: CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c; NA, non‐applicable; OGTT, oral glucose tolerance test; SMBG, self‐monitored blood glucose; T1D, type 1 diabetes. Recommendations presented in Table 3 adapted from “Consensus guidance for monitoring individuals with islet autoantibody‐positive pre‐stage 3 type 1 diabetes” [2] and “The T1D Early Detection Toolkit: A Practical Guide to Establishing Islet Autoantibody Screening Programs” [37]. Adjust frequency based on individual risk assessment, based on age number and type of islet autoantibodies, and glycemic status [2, 37]. In children with stage 1 T1D, this can be a sign of disease progression even if the 10% HbA1c increase is within the normal range (e.g., from 31 mmol/mol [5.0%] to 37 mmol/mol [5.5%]) [2]. TABLE 4Key considerations for HCPs – monitoring.Determine monitoring approach [2] (Primary or secondary setting) Determine the appropriate metabolic tests to be done and their frequency a Invite individual for periodic monitoring and management [2] (Primary or secondary setting) Establish a personalized monitoring plan based on patient results and history (e.g., their diagnosed stage, age, and risk factors), and clinical guidanceEnsure monitoring is coordinated with secondary/tertiary care providers and other specialistsReview results immediately at each appointment, before the individual leaves, so that if DKA risk is present, urgent referral or intervention can be initiatedInform individuals and caregivers of the next steps Discuss lifestyle changes and provide ongoing education [2, 38] (Primary or secondary setting) Provide education on key lifestyle and self‐management skills relevant to early‐stage T1D and how lifestyle changes can support overall healthDiscuss physical activity as an important component of metabolic health with information on how it can influence insulin needs, cardiovascular risk in adults, and overall well‐beingProvide education on healthy meal planning for children, to mitigate against disordered eating behaviours that could affect weight trendsProvide written information with neutral, fear‐free language, and emergency contact details for how to recognize T1D symptoms and hyperglycemia within monitoring plansProvide information on home glucose testing and device use, for example, SMBG meters and strips for use during illness or when symptoms occurUse clear, neutral language and if available, provide written, age‐appropriate educational materials/adviceOffer information on local psychosocial support, diabetes education programs or trusted online resources Identify and respond to changes in individual's status [2] (Primary or secondary setting) Review any identified changes in metabolic status or islet autoantibody statusRe‐evaluate the individual's T1D stage and adjust the monitoring plan as necessaryIf an individual with islet autoantibodies develops symptomatic hyperglycemia, provide an immediate consultation and referral to a multidisciplinary specialist diabetes teamDiscuss implications of changes with the individual/caregiver and outline the immediate next stepsUse empathetic, clear language and tone when communicating change in stage and if available, provide written materials with neutral, fear‐free language Abbreviations: CGM, continuous glucose monitoring; C‐peptide, connecting peptide; DKA, diabetic ketoacidosis; HCP, healthcare professional; SMBG, self‐monitored blood glucose; T1D, type 1 diabetes. a Monitoring may involve standard OGTT, random glucose, HbA1c, CGM, SMBG, C‐peptide, and repeat antibody testing [2]. Serial stimulated C‐peptide measurement during OGTT can be used to assess beta‐cell function decline and predict risk of developing T1D, highlighting the value of growth and beta‐cell function monitoring in providing early warning of progression [2]. Key considerations for HCPs – monitoring. Determine the appropriate metabolic tests to be done and their frequency a Determine the appropriate metabolic tests to be done and their frequency a Establish a personalized monitoring plan based on patient results and history (e.g., their diagnosed stage, age, and risk factors), and clinical guidance Establish a personalized monitoring plan based on patient results and history (e.g., their diagnosed stage, age, and risk factors), and clinical guidance Ensure monitoring is coordinated with secondary/tertiary care providers and other specialists Ensure monitoring is coordinated with secondary/tertiary care providers and other specialists Review results immediately at each appointment, before the individual leaves, so that if DKA risk is present, urgent referral or intervention can be initiated Review results immediately at each appointment, before the individual leaves, so that if DKA risk is present, urgent referral or intervention can be initiated Inform individuals and caregivers of the next steps Inform individuals and caregivers of the next steps Provide education on key lifestyle and self‐management skills relevant to early‐stage T1D and how lifestyle changes can support overall health Provide education on key lifestyle and self‐management skills relevant to early‐stage T1D and how lifestyle changes can support overall health Discuss physical activity as an important component of metabolic health with information on how it can influence insulin needs, cardiovascular risk in adults, and overall well‐being Discuss physical activity as an important component of metabolic health with information on how it can influence insulin needs, cardiovascular risk in adults, and overall well‐being Provide education on healthy meal planning for children, to mitigate against disordered eating behaviours that could affect weight trends Provide education on healthy meal planning for children, to mitigate against disordered eating behaviours that could affect weight trends Provide written information with neutral, fear‐free language, and emergency contact details for how to recognize T1D symptoms and hyperglycemia within monitoring plans Provide written information with neutral, fear‐free language, and emergency contact details for how to recognize T1D symptoms and hyperglycemia within monitoring plans Provide information on home glucose testing and device use, for example, SMBG meters and strips for use during illness or when symptoms occur Provide information on home glucose testing and device use, for example, SMBG meters and strips for use during illness or when symptoms occur Use clear, neutral language and if available, provide written, age‐appropriate educational materials/advice Use clear, neutral language and if available, provide written, age‐appropriate educational materials/advice Offer information on local psychosocial support, diabetes education programs or trusted online resources Offer information on local psychosocial support, diabetes education programs or trusted online resources Review any identified changes in metabolic status or islet autoantibody status Review any identified changes in metabolic status or islet autoantibody status Re‐evaluate the individual's T1D stage and adjust the monitoring plan as necessary Re‐evaluate the individual's T1D stage and adjust the monitoring plan as necessary If an individual with islet autoantibodies develops symptomatic hyperglycemia, provide an immediate consultation and referral to a multidisciplinary specialist diabetes team If an individual with islet autoantibodies develops symptomatic hyperglycemia, provide an immediate consultation and referral to a multidisciplinary specialist diabetes team Discuss implications of changes with the individual/caregiver and outline the immediate next steps Discuss implications of changes with the individual/caregiver and outline the immediate next steps Use empathetic, clear language and tone when communicating change in stage and if available, provide written materials with neutral, fear‐free language Use empathetic, clear language and tone when communicating change in stage and if available, provide written materials with neutral, fear‐free language Abbreviations: CGM, continuous glucose monitoring; C‐peptide, connecting peptide; DKA, diabetic ketoacidosis; HCP, healthcare professional; SMBG, self‐monitored blood glucose; T1D, type 1 diabetes. Monitoring may involve standard OGTT, random glucose, HbA1c, CGM, SMBG, C‐peptide, and repeat antibody testing [2]. Serial stimulated C‐peptide measurement during OGTT can be used to assess beta‐cell function decline and predict risk of developing T1D, highlighting the value of growth and beta‐cell function monitoring in providing early warning of progression [2]. Education and Psychosocial Support Screening, staging, diagnosis, and monitoring early‐stage T1D can provoke anxiety and uncertainty, even when islet autoantibody tests are negative, and are commonly associated with psychological distress, including fear and shock [39, 40]. Education outlining the individual's current status and anticipated next steps of the pathway should therefore be provided at all steps to maintain engagement, reduce distress, and help individuals and families adapt to lifestyle changes [2, 10]. Any educational resources, for example those covering symptom recognition, healthy coping strategies, and practical self‐management skills, should be co‐developed with psychologists where available to ensure content is age‐appropriate, culturally sensitive and delivered empathetically, with tailoring based on rate of progression and family circumstances [2, 7]. HCPs should use neutral, fear‐free language, outline objectives, procedures and timings for tests and provide written materials where feasible [2, 7]. 1 While psychosocial resources are an important component of care, their impact can be limited if used in isolation. Mental health screening is still uncommon in diabetes clinics, with 57% of adults with diabetes in an international survey reporting that mental well‐being had never been raised by their diabetes team [41]. Psychological services are often commissioned as an “afterthought” or seen as “nice to have” rather than an integral component of care, and a decade after the DAWN2 study, no measurable improvement in psychological outcomes has been observed for people with diabetes [41]. Moreover, relying on signposting to charities or helplines may place the burden on patients to initiate difficult conversations rather than embedding these discussions into routine care [41]. These issues highlight the need to integrate psychosocial resources and mental health support across all stages of the pathway, making them standard, proactive components rather than optional extras. Integration of routine psychological check‐ins into medical visits can normalize discussions about emotional well‐being, allow concerns to be addressed early, and support adherence and engagement [7, 42]. Each routine medical visit should ideally be led by professionals with diabetes‐specific training in early‐stage T1D and include assessment of emotional, cognitive, and behavioural functioning as well as psychological engagement [2]. Specific attention should be given to anxiety, risk perception, and coping needs [2]. Peer support networks and patient education programs may be able to complement clinical care by encouraging resilience, improving self‐management skills, and providing reassurance to those living with T1D (see Supporting Information for specific examples). Integrating available resources into care may enhance engagement and also contribute to better long‐term well‐being for individuals and families affected by early‐stage T1D. Discussion and Conclusion Here we present proposed care pathways for adults and children with early‐stage T1D, accompanied by practical, stage‐specific recommendations to support clinical implementation. These pathways aim to standardize key elements of care and highlight opportunities across the early‐stage T1D journey. Because health systems and local practices vary, a single universal pathway is not feasible; however, the principles and considerations described can be adapted to diverse settings. Across all stages of early‐stage T1D, effective continuity of care requires collaboration between primary care and endocrinologists; children and young adults should be evaluated by a pediatric endocrinologist and, where appropriate, referred to specialized centers for further assessment or treatment [7, 8]. In adults, slower progressing T1D should be considered, as such characteristics may resemble T2D clinically but remain autoimmune in origin [43]. Besides monitoring and education, we are now entering a time where individuals in early‐stage T1D and those just entering stage 3 T1D can be offered disease modifying interventions. The first disease modifying therapy, teplizumab, has now been approved by regulatory bodies worldwide for use in stage 2 T1D, with numerous clinical trials currently underway [44]. Networks like INNODIA, TrialNet, the UK Type 1 Diabetes Research Consortium, and the Australasian Type 1 Diabetes Immunotherapy Collaborative facilitate such trials and individuals eligible for these trials should be offered the opportunity to participate [21, 45, 46, 47]. Families should know whom to contact for advice and coordination and receive support in managing progression to later stages of T1D [7]. This can be complemented by structured, periodic education sessions and brief written or electronic reminders, highlighting key alert signs and symptoms of progression. Optional recall systems that provide active outreach and tracking help ensure attendance at scheduled follow‐ups, education sessions, and completion of recommended testing. These systems should be implemented with the individual's consent, in accordance with local policy, and designed to support, rather than replace, self‐management, for example through written or electronic reminders. HCPs with psychological communication training can further strengthen interactions, ensuring information is conveyed empathetically and clearly. Although while HCP communication training is important, educational materials alone cannot replace embedded psychological support. Mental health needs should be proactively addressed within the early‐stage T1D pathway, rather than relying on individuals to raise them. The timing and frequency of follow‐up in early‐stage T1D should be guided by disease stage, individual risk profile and available resources, with structured local protocols established to coordinate care across primary, secondary, and tertiary settings. Laboratory assessments (HbA1c, C‐peptide, repeat islet autoantibodies), clinical visits, and potential use of CGM should be scheduled according to guidelines and local practice. In lower‐resource settings or where reimbursement is limited, intervals may be extended, with higher‐risk individuals prioritized for more frequent monitoring. Clear guidance on screening methods and monitoring responsibilities is essential to ensure consistent care and to support families in understanding the rationale for ongoing assessments. Communicating the potential for disease progression and the purpose of monitoring in a sensitive, supportive manner may enable families to make informed decisions, prepare for future care needs and engage effectively with the healthcare team. However, implementation of structured early‐stage T1D care pathways may be challenging due to a need for education among HCPs, individuals, and caregivers, screening‐related anxiety, and limited access to psychologists and endocrinologists. Addressing these barriers is essential to enable streamlined care delivery, reduce diagnostic stress, and help maintain trust between individuals, families, and healthcare teams, ultimately reducing the risk of DKA and hospitalization. Finally, continuity of care and well‐coordinated transitions from early detection through ongoing monitoring within each healthcare system is essential. Establishing clear mechanisms for coordination and communication can provide reassurance for individuals and families and help support sustained engagement with early‐stage T1D care. Funding This work was supported by Sanofi. Conflicts of Interest C.M. serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for C.M. from Dexcom, Novo Nordisk and Sanofi; C.M. serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. C.M. is president of EUDF. All external support of EUDF can be found on https://www.eudf.org. V.C. has received speaker honoraria from Novo Nordisk, Sanofi, and Theras. His institution has received research grants from Lilly, Medtronic, and Movi. TMK received speaker honoraria from Abbott, Lilly, Merck serono, Medtronic, Novo Nordisk, Sanofi. He participated in Advisory Boards from Abbott and Sanofi. N.G.P.V. has received consulting fees from Sanofi and has participated in advisory boards for Sanofi. G.G. has received research grants from Sanofi, Chiesi, Alexion, Takeda, Lundbeck, Angelin. A.B. has received consulting fees from Sanofi and has participated in advisory boards for Sanofi. A.P. declares having received fees for occasional interventions (clinical trials, scientific work, advisory activity, conferences, or symposiums) from the companies Abbott, AstraZeneca, Diabeloop, Insulet, Isis, Medtronic, Medtrum, Novo Nordisk, Sanofi Winthrop, Eli Lilly. JMG is an employee of Sanofi. Prior to joining Sanofi, JMG received consulting fees from DRI Healthcare and advisory board fees from Eli Lilly and Company, Medtronic, VTV Therapeutics, and Sanofi. M.B. is an employee of Sanofi. M.A.M.‐B. has participated in advisory boards for Sanofi and is principal investigator in clinical trials sponsored by Diamyd Medical A.B. and Sanofi. K.H. has received consulting fees from Sanofi, MannKind, Embecta, and Havas Health. TLR has participated in advisory boards for Sanofi and has received speaker honoraria from and consulted with Abbott and Novo Nordisk. R.Z. has received speaker honoraria from and consulted with Abbott, Dexcom, mySugr, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi, Vertex and VitalAire. P.N. has served on advisory boards for Sanofi and Abbott and has received speaker fees and obtained support for conference attendance from Sanofi. P.N. has received grants from Helmsley Charitable Trust, Breakthrough T1D, and Diabetes UK. CDB has participated in advisory boards for Sanofi and is a member of Glooko clinical advisory board. Supporting information Appendix SI: Consensus guidance and guidelines are provided by the following organizations: the American Diabetes Association (ADA) Standards of Care, Breakthrough T1D consensus guidance, and the European Association for the Study of Diabetes (EASD). Appendix SII: DigiBete is in the process of developing age‐appropriate videos and an app tailored for children and young people [48]. Other global initiatives like Beyond Type 1, which raises awareness, provides life‐saving resources, and fosters community support, and Children with Diabetes, an international online forum and conference series, offer additional platforms for shared experiences and practical support [49, 50]. Appendix SIII: Screening for presymptomatic type 1 diabetes may be performed by detecting autoantibodies to insulin (IAA), glutamic acid decarboxylase (GAD), islet antigen‐2 (IA‐2/IA‐2A), or zinc transporter 8 (ZnT8), which are the clinically available biochemical autoantibodies recommended for screening [2, 8]. Testing should be performed using standardized assays, and the first positive result should be confirmed with a second test within 3 months, preferably in a laboratory meeting the performance standards set by the Islet Autoantibody Standardization Program (IASP) [2, 8]. Healthcare providers should consult local laboratories to confirm which assays are available and preferred, and clearly communicate the expected procedures to individuals. Figure S1: The Care Pathway. Acknowledgements Funding for this manuscript and the CARE‐T1D working group was provided by Sanofi. CARE‐T1D working group members received honoraria for participation in advisory boards; however, the recommendations and proposed pathways presented in this manuscript were developed independently of Sanofi. The CARE‐T1D working group comprised of Chantal Mathieu, Valentino Cherubini, Thomas Kapellen, Noemí González Pérez de Villar, Guendalina Graffigna, Alix Besancon, Alfred Penfornis, Justin Gregory, Monica Bertolini, María Asunción Martínez‐Brocca, Korey Hood, Tabitha Randell, Ralph Ziegler, Parth Narendran, and Carla Demeterco‐Berggren. The group provided expert guidance on early‐stage T1D care pathways. We thank the individuals for participating in interviews used to inform this work. Interviews were conducted without compensation for participants. Medical writing support was provided by Maya Gilbert, Alexis Crieta, and Alex Watson from VML Health and was funded by Sanofi. We also acknowledge the support of Guillaume Favier, Kate Ashurst, and Helena Szpytman from KPMG in developing the methodology for this work. Mathieu C., Cherubini V., Kapellen T., et al., “Advancing Early‐Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring,” Diabetes, Obesity and Metabolism 28, no. 8 (2026): 6836–6849, 10.1111/dom.70688. Handling Editor: Richard Donnelly Endnotes A list of materials should be available at a hospital or country level, and HCPs should refer to local diabetes organizations where possible. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Supplementary Materials Appendix SI: Consensus guidance and guidelines are provided by the following organizations: the American Diabetes Association (ADA) Standards of Care, Breakthrough T1D consensus guidance, and the European Association for the Study of Diabetes (EASD). Appendix SII: DigiBete is in the process of developing age‐appropriate videos and an app tailored for children and young people [48]. Other global initiatives like Beyond Type 1, which raises awareness, provides life‐saving resources, and fosters community support, and Children with Diabetes, an international online forum and conference series, offer additional platforms for shared experiences and practical support [49, 50]. Appendix SIII: Screening for presymptomatic type 1 diabetes may be performed by detecting autoantibodies to insulin (IAA), glutamic acid decarboxylase (GAD), islet antigen‐2 (IA‐2/IA‐2A), or zinc transporter 8 (ZnT8), which are the clinically available biochemical autoantibodies recommended for screening [2, 8]. Testing should be performed using standardized assays, and the first positive result should be confirmed with a second test within 3 months, preferably in a laboratory meeting the performance standards set by the Islet Autoantibody Standardization Program (IASP) [2, 8]. Healthcare providers should consult local laboratories to confirm which assays are available and preferred, and clearly communicate the expected procedures to individuals. Figure S1: The Care Pathway. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.